Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4+Foxp3+ Regulatory T Cells Differentiation

Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4+Foxp3+ Regulatory T Cells Differentiation

Apremilast is a novel phosphodiesterase 4 (PDE4) inhibitor suppressing immune and inflammatory responses. We assessed the anti-inflammatory effects of Apremilast in type II collagen (CII)-induced arthritis (CIA) mouse model. To determine whether Apremilast can ameliorate arthritis onset in this mode...

Full description

Bibliographic Details
Main Authors: Weiqian Chen, Julie Wang, Zhenjian Xu, Feng Huang, Wenbin Qian, Jilin Ma, Hwa bok Wee, Gregory S. Lewis, Rayford R. June, Peter H. Schafer, Jin Lin, Song Guo Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-07-01
Series:Frontiers in Immunology
Subjects:
rheumatoid arthritis
collagen CII-induced arthritis
phosphodiesterase 4
Apremilast
regulatory T and Th17 cells
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01662/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.01662/full

Similar Items